By Clifton Leaf and Sy Mukherjee
August 16, 2017

Good morning, readers! This is Sy.

Shares of biotech giant Biogen rose 2.5% in early Wednesday trading thanks to a boost from Goldman Sachs, which has added the company to its Americas Conviction List. That means that Goldman analysts believe Biogen has enough upside that they’re issuing their highest rating for its stock, a “Conviction Buy.”

Just what’s driving the enthusiasm? It’s all about Biogen’s audacious Alzheimer’s drug ambitions. The company’s experimental aducanumab “could be one of the first disease-modifying drugs to reach the market,” wrote the analysts, adding that if it does win regulatory clearance, it could reach peak sales of $12 billion considering the rapidly-growing burden of the disease.

The treatment has shown some early promise, but Alzheimer’s is a notoriously difficult (and from an R&D standpoint, heartbreaking) space. For instance, both Eli Lilly and Merck were forced to stop work after their own failures in Alzheimer’s treatment.

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

SPONSORED FINANCIAL CONTENT

You May Like